In a dramatic departure from its traditional focus on calorie counting and group weigh-ins, WeightWatchers has announced a new strategic partnership in the UK with CheqUp, a provider of GLP-1 weight-loss medications such as Wegovy and Mounjaro.
The move marks a major shift for the iconic brand, which is now aligning itself with the booming market for anti-obesity injections.
The partnership comes just weeks after WeightWatchers filed for Chapter 11 bankruptcy protection in the US, a move driven by mounting debts and a declining customer base, as more people turn to medication rather than meal plans for weight loss.
Under the agreement, CheqUp patients prescribed GLP-1 medications will gain access to a customised version of the WeightWatchers app, designed specifically to support those on weight-loss injections. The platform offers expert-guided food recommendations, aimed at reducing medication side effects like nausea while promoting healthy, sustainable weight loss.
“The data is clear — our members on obesity medications who also participate in our nutritional and behavioural lifestyle programme lose 11% more weight on average than those using the medication alone,” said Scott Honken, Chief Commercial Officer at WeightWatchers.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
